Unifactorial prediction of the risks of development and progression of cardiovascular diseases
- 作者: Derbeneva S.A.1, Pogozheva A.V.1, Shmeleva S.V.2, Sabanchieva Z.K.3
-
隶属关系:
- Federal Research Center for Nutrition and Biotechnology
- Moscow State University of Technology and Management n.a. K.G. Razumovsky
- Kabardino-Balkarian State University n.a. Kh.M. Berbekov
- 期: 卷 31, 编号 4 (2024)
- 页面: 48-53
- 栏目: Cardiology
- URL: https://bakhtiniada.ru/2073-4034/article/view/270881
- DOI: https://doi.org/10.18565/pharmateca.2024.4.48-53
- ID: 270881
如何引用文章
详细
Background. Prevention of cardiovascular diseases requires early identification of people at high risk so that effective dietary, lifestyle, or drug interventions can be implemented.
Objective. Evaluation of the clinical, instrumental and laboratory parameters as markers of the development and progression of cardiovascular diseases (CVDs).
Methods. Assessment of actual nutrition and physical activity at home, anthropometric studies, assessment of body composition, study of energy metabolism with determination of daily nitrogen excretion, study of indicators of resting metabolism and macronutrient metabolism. Laboratory studies included the general blood test, clinical urinalysis, analysis of biochemical markers of lipid, protein and carbohydrate metabolism, parameters of the functional activity of the hepatobiliary system, blood coagulation system, hormonal profile indicators, electrolyte metabolism, vitamin status, lipid peroxidation products and enzymes of the antioxidant protection system.
Results. In 956 patients with cardiovascular diseases, specific factors predicting the development of coronary artery disease (CAD) were identified: silent myocardial ischemia, post-infarction cardiosclerosis, condition after surgical treatment, angina pectoris 1 functional class. Prediction of the risk of developing a particular clinical event from specific quantitative or binary indicators of the metabolic status of patients was carried out using the Pearson Chi-square test.
Conclusion. In one clinical case of CAD, biomarkers of metabolic status were identified as key, in another case – parameters of the clinical course of atherosclerotic disease, in the third and fourth – their combination. Taking into account the presence of these factors, it is possible to carry out measures for their adequate and timely correction, thereby preventing the development and progression of these nosological forms.
作者简介
S. Derbeneva
Federal Research Center for Nutrition and Biotechnology
Email: 89151479832@mail.ru
ORCID iD: 0000-0003-1876-1230
俄罗斯联邦, Moscow
A. Pogozheva
Federal Research Center for Nutrition and Biotechnology
Email: 89151479832@mail.ru
ORCID iD: 0000-0003-4619-291X
俄罗斯联邦, Moscow
Svetlana Shmeleva
Moscow State University of Technology and Management n.a. K.G. Razumovsky
编辑信件的主要联系方式.
Email: 89151479832@mail.ru
Dr. Sci. (Med.), Professor
俄罗斯联邦, MoscowZh. Sabanchieva
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Email: 89151479832@mail.ru
ORCID iD: 0000-0002-9103-0648
俄罗斯联邦, Nalchik
参考
- Eckel R.H., Jakicic J.M., Ard J.D. American College of Cardiology/American Heart Association Practice Guidelines Task Force. 2013 AHA/ACC Guidelines for Lifestyle Management to Reduce Cardiovascular Disease Risk: American College of Cardiology/American Heart Association Practice Guidelines Task Force Report. Circulation. 2014;129(Appendix 2):S76–99. doi: 10.1161/01.CIR.0000437740.48606.d1.
- World Health Organization. Global status report on non-communicable diseases. URL: http://apps.who.int/iris/bitstream/10665/44579/1/9789240686458_eng. pdf. (20 June 2018).
- Holt A., Batinica B., Liang J., et al. Development and validation of cardiovascular risk prediction equations in 76 000 people with known cardiovascular disease. Eur J Prev Cardiol. 2024;31(2):218–27. doi: 10.1093/eurjpc/zwad314.
- Goff D.C., Lloyd-Jones D.M., Bennett G., et al. 2013 ACC/AHA Guidelines for Cardiovascular Risk Assessment: A Report from the American College of Cardiology/American Heart Association Practice Guidelines. Circulation. 2014;129:S49–73. doi: 10.1161/01.cir.0000437741.48606.98.
- WHO working group on CVD risk matrix. World Health Organization Cardiovascular Disease Risk Charts: Revised Models for Risk Assessment in 21 Regions of the World. Lancet Glob Health 2019;7:e1332–45. doi: 10.1016/S2214-109X(19)30318-3.
- Hippisley-Cox J., Copeland K., Tigrovoy. Development and validation of QRISK3 risk prediction algorithms for estimating future cardiovascular disease risk: a prospective cohort study. BMJ. 2017;357:J2099. doi: 10.1136/bmj.j2099.
- Helgason H., Eiriksdуttir T., Ulfбrsson M.O., et al. Evaluation of large-scale proteomics for predicting cardiovascular events. JAMA. 2023;330(8):725–35. doi: 10.1001/jama.2023.13258.
- Lazceroni D., Coruzzi P. Risk stratification in secondary prevention of cardiovascular diseases. Minerva Cardioangiol. 2018;66(4):471–76. doi: 10.23736/S0026-4725.18.04648-0.
- Benincasa G., Suades R., Padro T., et al. Bioinformatic platforms for the clinical stratification of the natural history of atherosclerotic cardiovascular diseases. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):758–69. doi: 10.1093/ehjcvp/pvad059.
- Akya R.K., Leonardi-B J., Asselbergs F.V., et al. Prediction of major adverse cardiovascular events for secondary prevention: a protocol for systematic review and meta-analysis of risk prediction models. BMJ Open. 2020;10(7):E034564. doi: 10.1136/bmjopen-2019-034564.
补充文件
